Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy
05 oct. 2020 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Company plans to seek end-of-phase meeting with Australia’s Therapeutic Goods Administration in Q1 2021 KNOXVILLE, TN, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today...
New Firm to Bring Alternative Investment Strategy to Mutual Fund Space
15 oct. 2012 13h10 HE
|
CARF
ATLANTA, GA--(Marketwire - Oct 15, 2012) - FISCO Funds Management LLC, a U.S.-based family of alternative investment managers, and OP 8 Analytics LLC today announced a joint venture to launch a new...